Physician profile
David White
NPI 1952344392
$2,355.47
in general payments reported to CMS, 2019-2025
23 companies · $680 in 2025
The $680 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.85 · 2020: $49.08 · 2021: $66.31 · 2022: $99.49 · 2023: $698 · 2024: $685 · 2025: $680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,062.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,061.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $618.86 | 2023-2025 | Evenity, Repatha, Prolia |
| Glaxosmithkline, LLC. | $315.49 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $272.76 | 2021-2025 | Jardiance, Tradjenta |
| Pfizer INC. | $190.07 | 2023-2025 | |
| Lilly USA, LLC | $131.56 | 2023-2024 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $117.09 | 2022-2024 | Ozempic, Rybelsus, Tresiba |
| Phathom Pharmaceuticals, INC. | $113.03 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals Lp | $110.94 | 2022-2024 | Breztri, Airsupra, Farxiga |
| Esperion Therapeutics, INC. | $70.10 | 2024-2025 | Nexletol |
| Exact Sciences Corporation | $69.95 | 2024-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $56.12 | 2024-2025 | |
| Ibsa Pharma INC. | $48.10 | 2022 | |
| Merck Sharp & Dohme LLC | $42.57 | 2023-2025 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Idorsia Pharmaceuticals US INC | $35.25 | 2023 | Quviviq |
| Medtronic, INC. | $24.65 | 2025 | Propel |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $21.08 | 2024 | Axonics |
| Eisai INC. | $19.92 | 2024 | |
| Shield Therapeutics INC | $18.76 | 2025 | |
| Abbvie INC. | $17.34 | 2023 | Linzess, Creon |
| Kowa Pharmaceuticals America, INC. | $16.65 | 2024 | Livalo |
| Corcept Therapeutics | $16.63 | 2025 | Korlym |
| Abbott Laboratories | $14.57 | 2023 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $13.98 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.